DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.41
+1.54 (31.62%)
At close: Dec 20, 2024, 4:00 PM
5.65
-0.76 (-11.86%)
After-hours: Dec 20, 2024, 7:58 PM EST
DiaMedica Therapeutics Employees
As of December 31, 2023, DiaMedica Therapeutics had 19 total employees, including 18 full-time and 1 part-time employees. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,142,368
Market Cap
274.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SOPHiA GENETICS | 430 |
ADC Therapeutics | 274 |
LifeMD | 211 |
biote | 194 |
Utah Medical Products | 190 |
Inhibrx Biosciences | 172 |
Zentalis Pharmaceuticals | 124 |
Acrivon Therapeutics | 61 |
DMAC News
- 18 days ago - DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - Business Wire
- 5 weeks ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 5 weeks ago - DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
- 6 weeks ago - DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 3 months ago - DiaMedica Therapeutics Upcoming Conference Participation - Business Wire